PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-κB-dependent proinflammatory activation of alveolar epithelial cells

British Journal of Pharmacology

Volumn 155, Issue 5, 2008, Pages 661-672

  Callister, M E ^a   Pinhu, L ^a   Catley, M C ^a   Westwell, A D ^b   Newton, R ^c   Leaver, S K ^a   Quinlan, G J ^a   Evans, T W ^a   Griffiths, M J ^a   Burke Gaffney, A ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

A549 epithelial cells; CXCL8; GM CSF; ICAM 1; NF B pathway; PMX464; Quinol; Thioredoxin; Thioredoxin reductase; Trx siRNA

Indexed keywords

AW 464; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; I KAPPA B; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; PMX 464; PROTEIN INHIBITOR; SMALL INTERFERING RNA; THIOL REACTIVE QUINOL; THIOREDOXIN INHIBITOR; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RESPIRATORY TRACT INFLAMMATION; RNA INTERFERENCE;

ANIMALS; BENZOTHIAZOLES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYCLOHEXANONES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; HYDROQUINONES; IMMUNOBLOTTING; MICROSCOPY, CONFOCAL; NEUTROPHILS; NF-KAPPA B; PULMONARY ALVEOLI; RNA, SMALL INTERFERING; THIOREDOXINS;

EID: 54949154541     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.258     Document Type: Article

References (39)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd ed. Brit J Pharmacol 153 (Suppl 2): S1-S209.
2. Bergmann M, Hart L, Lindsay M, Barnes PJ, Newton R (1998). IkappaBalpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem 273: 6607-6610.
3. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J et al. (2005). Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 172: 962-971.
4. Blease K, Chen Y, Hellewell PG, Burke-Gaffney A (1999). Lipoteichoic acid inhibits lipopolysaccharide-induced adhesion molecule expression and IL-8 release in human lung microvascular endothelial cells. J Immunol 163: 6139-6147.
5. Burke-Gaffney A, Callister ME, Nakamura H (2005). Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26: 398-404.
6. Burke-Gaffney A, Hellewell PG (1996). Tumour necrosis factor-alpha-induced ICAM-1 expression in human vascular endothelial and lung epithelial cells: modulation by tyrosine kinase inhibitors. Br J Pharmacol 119: 1149-1158.
7. Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG, Florio R, Nakamura H et al. (2006). Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 61: 521-527.
8. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M et al. (2003). Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13: 2419-2422.
9. Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A et al. (2004). Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-kappaB DNA binding. J Biol Chem 279: 18457-18466.
10. Catley MC, Chivers JE, Holden NS, Barnes PJ, Newton R (2005). Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br J Pharmacol 145: 114-122.
11. Chew EH, Lu J, Bradshaw TD, Holmgren A (2008). Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22: 2072-2083.
12. Chew EH, Matthews CS, Zhang J, McCarroll AJ, Hagen T, Stevens MF et al. (2006). Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Biochem Biophys Res Commun 346: 242-251.
13. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
14. Dandreaa T, Bajaka E, Wärngårda L, Cotgreave IA (2002). Protein S-glutathionylation correlates to selective stress gene expression and cytoprotection. Arch Biochem Biophys 406: 241-252.
15. Freeman RE, Neuzil J (2006). Role of thioredoxin-1 in apoptosis induction by alpha-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett 580: 2671-2676.
16. Frelin C, Imbert V, Griessinger E, Loubat A, Dreano M, Peyron JF (2003). AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. Oncogene 22: 8187-8194.
17. Ghosh S, Karin M (2002). Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-S96.
18. Gorreta F, Runfola TP, VanMeter AJ, Barzaghi D, Chandhoke V, Del Giacco L (2005). Identification of thioredoxin reductase 1-regulated genes using small interference RNA and cDNA microarray. Cancer Biol Ther 4: 1079-1088.
19. Gupta S, Afaq F, Mukhtar H (2002). Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 21: 3727-3738.
20. Henderson Jr WR, Chi EY, Teo JL, Nguyen C, Kahn M (2002). A small molecule inhibitor of redox-regulated NF-kappa B and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 169: 5294-5299.
21. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. (2002). NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647.
22. Holmgren A, Bjornstedt M (1995). Thioredoxin and thioredoxin reductase. Methods Enzymol 252: 199-208.
23. Jeon KI, Byun MS, Jue DM (2003). Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med 35: 61-66.
24. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA et al. (1999). Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483.
25. Koura T, Gon Y, Hashimoto S, Azuma A, Kudoh S, Fukuda Y et al. (2000). Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation. Thorax 55: 755-761.
26. Lentsch AB, Ward PA (2000). The NFkappaBb/IkappaB system in acute inflammation. Arch Immunol Ther Exp (Warsz) 48: 59-63.
27. Lillig CH, Holmgrem A (2007). Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 9: 25-47.
28. Misra-Press A, McMillan M, Cudaback E, Qabar M, Ruan F, Nguyen M et al. (2002). Identification of a Novel Inhibitor of the NF-kB Pathway. Curr Med Chem-Anti-Inflammatory and Anti-Allergy Agents 1: 29-39.
29. Mukherjee A, Huber K, Evans H, Lakhani N, Martin S (2007). A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines. Br J Pharmacol 151: 1167-1175.
30. Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J, Martin SG (2005). Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 92: 350-358.
31. Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D et al. (2007). Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther 321: 734-742.
32. Pallis M, Bradshaw TD, Westwell AD, Grundy M, Stevens MF, Russell N (2003). Induction of apoptosis without redox catastrophe by thioredoxin- inhibitory compounds. Biochem Pharmacol 66: 1695-1705.
33. Rahman I, Yang SR, Biswas SK (2006). Current concepts of redox signaling in the lungs. Antioxid Redox Signal 8: 681-689.
34. Ravi D, Muniyappa H, Das KC (2005). Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 280: 40084-40096.
35. Soini Y, Kahlos K, Näpänkangas U, Kaarteenaho-Wiik R, Säily M, Koistinen P et al. (2001). Widespread Expression of Thioredoxin and Thioredoxin Reductase in Non-Small Cell Lung Carcinoma. Clin Cancer Res 7: 1750-1757,.
36. Souza DG, Vieira AT, Pinho V, Sousa LP, Andrade AA, Bonjardim CA et al. (2005). NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol 145: 246-254.
37. Tiitto L, Kaarteenaho-Wiik R, Sormunen R, Holmgren A, Paakko P, Soini Y et al. (2003). Expression of the thioredoxin system in interstitial lung disease. J Pathol 201: 363-370.
38. Trigona WL, Mullarky IK, Cao Y, Sordillo LM (2006). Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J 394: 207-216.
39. Wells G, Berry JM, Bradshaw TD, Burger AM, Seaton A, Wang B et al. (2003). 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 46: 532-541.